Company / Revenue
AVADEL PHARMACEUTICALS PLC Revenue History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$169.1M
FY2024
5-year range
$0 / $169.1M
FY2020-FY2024
Trend
+504.8%
vs FY2023
Sector context
#97 of 155
Health Care
What the data says
Revenue changed +505% YoY in FY2024, a notable deviation from the 7-year average annual change of +37%.
Based on SEC 10-K filings.
$169M in FY2024 with a 5-year CAGR of +23.4%.
Improved from $0 to $169M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +23.4%
- 10-Year CAGR
- -
Sector benchmark
#97 of 155 in Health CareTop 63% of 155This company $169.1M Sector average $4.5B
▼
-96.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +23.4%, indicating consistent growth.
- In FY2024, revenue increased 504.8% year-over-year.
- Ranks #97 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $169.1M | +504.8% |
| FY2023 | $28.0M | - |
| FY2022 | $0 | - |
| FY2021 | $0 | -100.0% |
| FY2020 | $22.3M | -62.3% |
| FY2019 | $59.2M | -42.7% |
| FY2018 | $103.3M | -40.4% |
| FY2017 | $173.2M | +15.3% |
| FY2016 | $150.2M | -13.2% |
| FY2015 | $173.0M | +1055.3% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026